Medtronic 2012 Annual Report Download - page 20

Download and view the complete annual report

Please find page 20 of the 2012 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 152

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152

The charts below set forth net sales of our CRDM products as a percentage of our total net sales for
each of the last three fiscal years:
Customers and Competitors
The primary medical specialists who use our CRDM products include electrophysiologists, implanting
cardiologists, heart failure specialists, and cardiovascular surgeons. Our primary competitors in the CRDM
business are St. Jude Medical, Inc. (St. Jude), Boston Scientific Corporation (Boston Scientific), Biotronik,
Inc., and Sorin Group.
CardioVascular
CardioVascular is composed of the following three businesses: Coronary, Endovascular and Peripheral,
and Structural Heart.
The Coronary business includes therapies to treat coronary artery disease (CAD) and hypertension.
The products contained within this business include coronary stents and related delivery systems, along
with a broad line of balloon angioplasty catheters, guide catheters, guidewires, diagnostic catheters, and
accessories. The following are the principal products offered by our Coronary business:
Percutaneous Coronary Intervention (PCI). PCI encompasses a variety of procedures used to treat
patients with CAD. CAD is commonly treated with balloon angioplasty, which is performed to open
narrowed heart vessels by inserting a balloon catheter into the vessel and advancing it to the site of the
blockage where it is inflated to widen the obstructed vessel. Balloon angioplasty can be followed up with a
coronary stent, a support device which works as scaffolding to keep the vessel open following the
intervention. Our PCI stent products include our Integrity, Driver, and Micro-Driver bare metal stent
systems as well as our Resolute, Resolute Integrity, and Endeavor drug-eluting coronary stent systems.
Renal Denervation. The Symplicity Catheter System is designed to treat chronic uncontrolled
hypertension by delivering radio frequency energy through the renal artery walls to denervate the renal
nerves, or ablate the nerves lining the renal arteries. This technology has received CE Mark approval and
is available in select markets. The Company is currently conducting a U.S. IDE study (HTN-3) for
U.S. approval.
The Endovascular and Peripheral business is comprised of a comprehensive line of products and
therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease (PVD). Our
products include endovascular stent graft systems, embolic protection systems, and stent systems for the
treatment of narrowed iliac arteries. The following are the principal products offered by our Endovascular
and Peripheral business:
Endovascular Stent Grafts. An endovascular stent graft is a minimally invasive device to repair an
aortic aneurysm, which is a weakened and bulging area in the aorta, the major blood vessel that feeds blood
to the body. Our products are designed to treat aortic aneurysms in either the abdomen (AAA) or thoracic
(TAA) regions of the aorta. Our product line includes a range of endovascular stent grafts including the
market-leading Endurant, Talent and AneuRx abdominal stent grafts for minimally invasive AAA and the
Talent, Talent Captivia, Valiant and Valiant Captivia (available in select markets outside the U.S.) stent
grafts for minimally invasive TAA repair.
3
CRDM
$5,007
All Other
$11,177
Fiscal Year 2012
(dollars in millions)
66%
34%
CRDM
$5,010
All Other
$10,498
Fiscal Year 2011
(dollars in millions)
CRDM
$5,268
All Other
$10,124
Fiscal Year 2010
(dollars in millions)
69%
31%
68%
32%